Keymed Biosciences Inc.
HKEX:2162.HK
43.25 (HKD) • At close November 5, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Keymed Biosciences Inc. |
Symbool | 2162.HK |
Munteenheid | HKD |
Prijs | 43.55 |
Beurswaarde | 12,002,380,000 |
Dividendpercentage | 0% |
52-weken bereik | 26.6 - 64.45 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bo Chen |
Website | https://www.keymedbio.com |
An error occurred while fetching data.
Over Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)